Genetic testing can guide personalized AMD treatment

Article

During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

Atlanta, GA-During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

While other factors, such as age, weight, and whether a patient smokes, nothing can help predict the likelihood of a patient developing AMD over the next 2, 5, and 10 years like a genetic test. The test can also tell the optometrist which types of therapy would be most beneficial to the patient.

“It’s bad to be a smoker, when it comes to AMD.  It’s bad to have bad genetics. It’s really bad to have bad genes and be a smoker,” says Dr. Gerson. He said patients with bad genetics are at a 400xs greater risk for developing AMD than those with good genetics, and adding in smoking or other factors make that risk increases even more.

Dr. Gerson says he uses the Macula Risk test, which requires the patient to swab the inside of her cheek. The test is sent off to a lab and results are ready within 2-3 weeks.

If a patient has a diagnosis of drusen or AMD and has insurance, the test costs the patient about $25, says Dr. Gerson. For patients without insurance, the test costs $500-$700.

In addition to identifying patients who are most at risk for AMD, it can bring peace of mind to those who find they are not at risk for the disease.

“Our role is to be preventative and proactive. I ask myself, ‘If this were my mom, what would I do?’ And wouldn’t it be great to tell someone ‘You don’t have to worry’?” says Dr. Gerson.

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.